These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34447812)

  • 1. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis.
    Zhang Y; Li JX; Zhang Y; Wang YL
    World J Clin Cases; 2021 Aug; 9(23):6654-6662. PubMed ID: 34447812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.
    Luo L; Chang Y; Sheng L
    Life Sci; 2023 May; 321():121614. PubMed ID: 36965522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD.
    Fernandez-Cantos MV; Garcia-Morena D; Iannone V; El-Nezami H; Kolehmainen M; Kuipers OP
    Tissue Barriers; 2021 Jul; 9(3):1879719. PubMed ID: 34280073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis.
    Han H; Jiang Y; Wang M; Melaku M; Liu L; Zhao Y; Everaert N; Yi B; Zhang H
    Crit Rev Food Sci Nutr; 2023; 63(12):1689-1706. PubMed ID: 34404276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.
    Chen X; Liu M; Tang J; Wang N; Feng Y; Ma H
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Liu L; Yin M; Gao J; Yu C; Lin J; Wu A; Zhu J; Xu C; Liu X
    J Clin Transl Hepatol; 2023 Apr; 11(2):452-458. PubMed ID: 36643028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
    Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
    Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
    Shao L; Song Y; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):505-509. PubMed ID: 34225424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link.
    Effenberger M; Grander C; Grabherr F; Tilg H
    J Clin Transl Hepatol; 2023 Dec; 11(7):1498-1507. PubMed ID: 38161503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of the gut-liver axis to the immune signaling pathway of NAFLD.
    Liu J; Wu A; Cai J; She ZG; Li H
    Front Immunol; 2022; 13():968799. PubMed ID: 36119048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.
    Gil-Gómez A; Brescia P; Rescigno M; Romero-Gómez M
    Semin Liver Dis; 2021 May; 41(2):191-205. PubMed ID: 34107545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
    Wang T; Ishikawa T; Sasaki M; Chiba T
    Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology.
    Yang XF; Lu M; You L; Gen H; Yuan L; Tian T; Li CY; Xu K; Hou J; Lei M
    Chin Med; 2021 Jul; 16(1):62. PubMed ID: 34315516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.